Cullinan Therapeutics, Inc., a biopharmaceutical company specializing in modality-agnostic targeted therapies, has announced a new partnership with Genrix Bio. Under the agreement, Cullinan will pay an upfront license fee of $20 million for exclusive global rights, excluding Greater China, to develop and commercialize velinotamig, a BCMAxCD3 bispecific T cell engager. This collaboration aims to advance Cullinan's leadership in T cell engager development for autoimmune diseases, adding to their pipeline that already includes a CD19 TCE. Genrix Bio stands to receive up to $292 million in development and regulatory milestones, an additional $400 million in sales-based milestones, and tiered royalties from mid-single digits to mid-teens on potential net sales outside Greater China. Cullinan's strengthened portfolio positions them to address a broader range of diseases while maintaining financial resources into 2028.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.